贝伐单抗结合化疗治疗晚期结肠癌的生存分析  

Survival analysis of bevacizumab combining with chemotherapy in the treatment of advanced colon cancer patients

作　　者：刘洋[1] 尤振宇[1] 苏晓辉[2] 刘渤娜[1] 刘学飞[1] 

机构地区：[1]解放军第202医院肿瘤介入科,辽宁沈阳110003 [2]辽宁省肿瘤医院胃外科,辽宁沈阳110042

出　　处：《现代肿瘤医学》2015年第10期1394-1398,共5页Journal of Modern Oncology

基　　金：辽宁省科学技术计划项目(编号:2013225089)

摘　　要：目的:分析影响接受贝伐单抗结合化疗治疗晚期结肠癌患者生存情况的因素。方法:回顾性分析2008年5月至2012年5月期间接受贝伐单抗结合化疗治疗的60例晚期结肠癌患者的临床资料和随访记录,探讨治疗时间、心血管副反应、K-ras基因型、单器官转移部位及贝伐单抗维持治疗对生存期的影响。结果:接受治疗超过半年的患者中位无进展生存期(PFS)及总生存期(OS)长于治疗时间半年以内的患者,差异具有统计学意义(P=0.023;P=0.043)。出现心血管副反应的患者中位PFS及OS长于未出现心血管副反应的患者(P=0.014;P=0.032)。K-ras基因野生型和突变型患者的PFS及OS有统计学差异(P=0.024;P=0.039)。单器官转移至肝脏的患者与单器官转移到卵巢的患者,其PFS及OS无统计学差异(P=0.853;P=0.835)。行贝伐单抗维持治疗的患者,其OS长于未行维持治疗的患者(P=0.013)。结论:在贝伐单抗和化疗联合治疗的晚期结肠癌患者中,治疗时间和出现心血管副反应可能是患者的预后因素。行贝伐单抗维持治疗可使患者生存受益。Objective ：To analyze survival effect of bevacizumab combining with chemotherapy in the treatment of advanced colon cancer patients. Methods ：The clinical data of 60 patients with colon cancer were retrospectively analyzed who were received bevacizumab combining with chemotherapy. The effects of duration of exposure to bevacizumab and chemotherapy, adverse cardiovascular events, K - ras genotype, single organ metastatic site and maintenance therapy with bevacizumab on survival were investigated. Results： The patients those whose duration of exposure to bevacizumab and chemotherapy more than 6 months had longer median PFS and OS than those whose duration of exposure to bevacizumab and chemotherapy within 6 months （ P = 0. 023 ; P = 0. 043 ）. The median PFS and OS of patients those who had adverse cardiovascular events were longer than those who had not（P = 0. 014 ;P =0.032）. There were statistically differences of PFS and OS between the patients who carry wild - type K - ras gene and who carry mutant K - ras gene （ P = 0.024 ; P = 0.039）. There were not statistically differences of PFS and OS between the patients who had liver metastasis and ovary metastasis（P = 0. 853 ;P = 0.835）. The median PFS and OS of patients those who accepted maintenance therapy with bevacizumab were longer than those who had not（ P = 0. 013 ）. Conclusion：For the advanced colon cancer patients who received bevacizumab combining with chemotherapy, the duration of exposure to bevacizumab and chemotherapy and the adverse cardiovascular events may be the prognostic factor. Maintenance therapy with bevacizumab had significantly statistically survival advantage.

关 键 词：结肠癌 贝伐单抗 化疗 生存分析 预后 

分 类 号：R735.3[医药卫生—肿瘤]